Another phase I clinical trial demonstrated that the VXM01 vaccine was efficacious in inducing VEGFR2-specific effector T cell responses and attenuating tumor perfusion in 30 patients with advanced PC (102). This evidence concerns the gene KDR and pachyonychia congenita.